Newsroom

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of First Reliance Bancshares, Inc. (OTC: FSRL) to Colony Bankcorp, Inc. (NYSE: CBAN). Under the terms of the proposed transaction, shareholders of First Reliance will receive either $19.75 in cash or 0.94 of a share of Colony’s common stock for each share of First Reliance that they own. KSF is seeking...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Bio-Techne Corporation (NasdaqGS: TECH) to Merck KGaA. Under the terms of the proposed transaction, shareholders of Bio-Techne will receive $73.00 in cash for each share of Bio-Techne that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or...

OKLAHOMA CITY--(BUSINESS WIRE)--Gulfport Energy Corporation (NYSE: GPOR) (“Gulfport” or the “Company”) today announced the successful acquisition of approximately 4,700 net undeveloped acres in the core of the Ohio Utica in Belmont County, Ohio, through the Ohio Oil and Gas Land Management Commission State Land Lease Sale for a total purchase price of approximately $83.0 million. Key Highlights Large, contiguous acquisition of approximately 4,700 net undeveloped acres secured in a highly compet...

PECHINO--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315) oggi ha annunciato di aver vinto una sentenza civile di primo grado emessa dal Tribunale per la proprietà intellettuale di Shanghai. Il tribunale ha sentenziato che Biocytogen non ha violato i relativi diritti sui brevetti rivendicati dalla parte ricorrente, Harbour Antibodies BV ("Harbour"), e ha addebitato alla parte ricorrente le spese processuali. La sentenza rappresenta un impo...

CHICAGO--(BUSINESS WIRE)--Morningstar, Inc. (Nasdaq: MORN), plans to report its second-quarter 2026 financial results after the market closes on Wednesday, July 29, 2026. The company does not hold analyst conference calls; however, investors may submit written questions to Morningstar at investors@morningstar.com. About Morningstar Morningstar, Inc. is a leading provider of independent investment insights in North America, Europe, Australia, and Asia. The Company offers an extensive line of pro...

CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) will issue its second quarter 2026 earnings release after the close of trading on the New York Stock Exchange on Wednesday, July 29, 2026. A conference call to discuss those earnings will be held on Thursday, July 30, 2026 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). The dial-in number for the conference call is (888) 330-3576 (or +1 (646) 960-0672 for international callers), and the participant passcode is 7655497. A live webcast can b...

EWING, N.J.--(BUSINESS WIRE)--UDC today announced that Dr. Julie Brown, Executive Vice President and Chief Technical Officer, has been honored with the IEEE Frederik Philips Award....

VANCOUVER, British Columbia--(BUSINESS WIRE)--Capstone Copper Corp. (“Capstone” or the “Company”) (TSX:CS) (ASX:CSC) is pleased to announce that it has published its 2025 Sustainability Report (the “Sustainability Report” or the “Report”). The Report has been prepared in accordance with the Global Reporting Initiative (“GRI”) Standards, Sector Standard GRI 14: Mining Sector 2024, and the SASB Metals & Mining Sustainability Accounting Standard. The Report details the Company’s performance on...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of fixed duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, and lenalidomide, compared to standard-of-care, rituximab plus gemcitabine plus oxaliplatin (R-GemOx), in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received at least one prior line of treatme...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ('Biocytogen,' SSE: 688796; HKEX: 02315) heeft vandaag bekendgemaakt dat het een civielrechtelijke uitspraak in eerste aanleg heeft ontvangen van de Rechtbank voor Intellectuele Eigendom van Shanghai. De rechtbank oordeelde dat Biocytogen geen inbreuk heeft gemaakt op de relevante octrooirechten waarop eiser Harbour Antibodies BV ('Harbour') zich beriep, en veroordeelde de eiser tot het dragen van de proceskosten. Deze uit...